HUP0203032A3 - Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their use - Google Patents
Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their useInfo
- Publication number
- HUP0203032A3 HUP0203032A3 HU0203032A HUP0203032A HUP0203032A3 HU P0203032 A3 HUP0203032 A3 HU P0203032A3 HU 0203032 A HU0203032 A HU 0203032A HU P0203032 A HUP0203032 A HU P0203032A HU P0203032 A3 HUP0203032 A3 HU P0203032A3
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- pharmaceutical compositions
- crystalline form
- compositions containing
- dissolution rate
- Prior art date
Links
- 238000004090 dissolution Methods 0.000 title 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 title 1
- 229960001208 eplerenone Drugs 0.000 title 1
- 230000001747 exhibiting effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16969099P | 1999-12-08 | 1999-12-08 | |
| US16963999P | 1999-12-08 | 1999-12-08 | |
| US16955699P | 1999-12-08 | 1999-12-08 | |
| US16960899P | 1999-12-08 | 1999-12-08 | |
| US16980799P | 1999-12-08 | 1999-12-08 | |
| US16968299P | 1999-12-08 | 1999-12-08 | |
| PCT/US2000/032416 WO2001042272A2 (en) | 1999-12-08 | 2000-12-04 | Eplerenone crystalline form exhibiting enhanced dissolution rate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0203032A2 HUP0203032A2 (hu) | 2002-12-28 |
| HUP0203032A3 true HUP0203032A3 (en) | 2003-04-28 |
Family
ID=27558585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203032A HUP0203032A3 (en) | 1999-12-08 | 2000-12-04 | Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their use |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1177204A2 (zh) |
| JP (1) | JP2003516414A (zh) |
| KR (1) | KR100607923B1 (zh) |
| CN (2) | CN1557833A (zh) |
| AU (1) | AU784946B2 (zh) |
| BR (1) | BR0008057A (zh) |
| CA (1) | CA2362669A1 (zh) |
| CO (1) | CO5280211A1 (zh) |
| EA (1) | EA007934B1 (zh) |
| HK (1) | HK1050536A1 (zh) |
| HU (1) | HUP0203032A3 (zh) |
| IL (3) | IL144764A0 (zh) |
| MX (1) | MXPA01008056A (zh) |
| MY (1) | MY131878A (zh) |
| NO (1) | NO20013856L (zh) |
| NZ (2) | NZ530028A (zh) |
| PE (1) | PE20010917A1 (zh) |
| WO (1) | WO2001042272A2 (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003225871A1 (en) * | 2002-03-20 | 2003-10-08 | Pharmacia Corporation | Storage stable eplerenone formulation |
| US7235655B2 (en) | 2002-03-22 | 2007-06-26 | Pharmacia & Upjohn Company | Processes to prepare eplerenone |
| CA2582496A1 (en) | 2007-03-20 | 2008-09-20 | Apotex Pharmachem Inc. | Improved process for the preparation and purification of eplerenone |
| US8957052B2 (en) | 2010-05-10 | 2015-02-17 | Universite Paris Descartes | Methods and compositions for the treatment of fluid accumulation in and/or under the retina |
| US9241944B2 (en) | 2010-06-16 | 2016-01-26 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and compositions for stimulating reepithelialisation during wound healing |
| JP6835836B2 (ja) | 2015-10-13 | 2021-02-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 脈絡膜血管新生の処置のための方法及び医薬組成物 |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| CN108059648A (zh) * | 2017-12-30 | 2018-05-22 | 合肥久诺医药科技有限公司 | 一种依普利酮溶剂合物及其制备方法 |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
| WO2023204729A1 (ru) * | 2022-04-19 | 2023-10-26 | Общество с ограниченной ответственностью "Гелеспон" | Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559332A (en) * | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| ES2293944T3 (es) * | 1996-12-11 | 2008-04-01 | G.D. Searle Llc. | Procedimiento de epoxidacion. |
| PT1165136E (pt) * | 1999-03-05 | 2004-02-27 | Searle Llc | Terapia de combinacao de inibidores da enzima de conversao da antagonista da aldosterona epoxi-esteroidal para tratamento de doenca cardiovascular |
-
2000
- 2000-12-04 IL IL14476400A patent/IL144764A0/xx active IP Right Grant
- 2000-12-04 WO PCT/US2000/032416 patent/WO2001042272A2/en not_active Application Discontinuation
- 2000-12-04 EP EP00983781A patent/EP1177204A2/en not_active Withdrawn
- 2000-12-04 HU HU0203032A patent/HUP0203032A3/hu unknown
- 2000-12-04 CA CA002362669A patent/CA2362669A1/en not_active Abandoned
- 2000-12-04 NZ NZ530028A patent/NZ530028A/en not_active IP Right Cessation
- 2000-12-04 KR KR1020017010043A patent/KR100607923B1/ko not_active IP Right Cessation
- 2000-12-04 JP JP2001543569A patent/JP2003516414A/ja not_active Withdrawn
- 2000-12-04 MX MXPA01008056A patent/MXPA01008056A/es not_active Application Discontinuation
- 2000-12-04 CN CNA2004100368081A patent/CN1557833A/zh active Pending
- 2000-12-04 CN CNB008057788A patent/CN1152886C/zh not_active Expired - Fee Related
- 2000-12-04 NZ NZ513961A patent/NZ513961A/xx not_active IP Right Cessation
- 2000-12-04 BR BR0008057-8A patent/BR0008057A/pt not_active IP Right Cessation
- 2000-12-04 EA EA200100871A patent/EA007934B1/ru not_active IP Right Cessation
- 2000-12-04 AU AU20492/01A patent/AU784946B2/en not_active Ceased
- 2000-12-06 PE PE2000001300A patent/PE20010917A1/es not_active Application Discontinuation
- 2000-12-06 MY MYPI20005734A patent/MY131878A/en unknown
- 2000-12-11 CO CO00094075A patent/CO5280211A1/es not_active Application Discontinuation
-
2001
- 2001-08-06 IL IL144764A patent/IL144764A/en not_active IP Right Cessation
- 2001-08-08 NO NO20013856A patent/NO20013856L/no not_active Application Discontinuation
-
2003
- 2003-04-15 HK HK03102731A patent/HK1050536A1/xx not_active IP Right Cessation
-
2006
- 2006-06-22 IL IL176511A patent/IL176511A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL176511A (en) | 2007-08-19 |
| AU784946B2 (en) | 2006-08-03 |
| WO2001042272A2 (en) | 2001-06-14 |
| NO20013856L (no) | 2001-10-08 |
| CA2362669A1 (en) | 2001-06-14 |
| EA200100871A1 (ru) | 2002-04-25 |
| HUP0203032A2 (hu) | 2002-12-28 |
| PE20010917A1 (es) | 2001-09-10 |
| WO2001042272A9 (en) | 2002-12-12 |
| JP2003516414A (ja) | 2003-05-13 |
| KR20010112261A (ko) | 2001-12-20 |
| NO20013856D0 (no) | 2001-08-08 |
| AU2049201A (en) | 2001-06-18 |
| CN1377365A (zh) | 2002-10-30 |
| HK1050536A1 (en) | 2003-06-27 |
| MXPA01008056A (es) | 2003-07-21 |
| CO5280211A1 (es) | 2003-05-30 |
| CN1152886C (zh) | 2004-06-09 |
| NZ513961A (en) | 2004-02-27 |
| IL144764A0 (en) | 2002-06-30 |
| MY131878A (en) | 2007-09-28 |
| IL144764A (en) | 2007-08-19 |
| NZ530028A (en) | 2005-08-26 |
| KR100607923B1 (ko) | 2006-08-04 |
| CN1557833A (zh) | 2004-12-29 |
| EA007934B1 (ru) | 2007-02-27 |
| BR0008057A (pt) | 2002-04-23 |
| WO2001042272A3 (en) | 2001-11-29 |
| EP1177204A2 (en) | 2002-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300618A3 (en) | Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0203548A3 (en) | New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0204245A3 (en) | Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0203902A3 (en) | Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use | |
| HUP0203316A3 (en) | Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0204515A3 (en) | 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0203122A3 (en) | Fab i inhibitors, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0300616A3 (en) | Adamantane derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0105114A3 (en) | Quinazolinone derivatives, pharmaceutical compositions containing them, their use and process for their preparation | |
| HUP0303529A3 (en) | New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use | |
| HUP0301069A3 (en) | Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0201516A2 (en) | 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0201753A3 (en) | Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0202075A3 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0201402A3 (en) | Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them | |
| HUP0203184A3 (en) | Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0202934A3 (en) | Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof | |
| HUP0202731A3 (en) | O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0204318A3 (en) | Torsemide polymorphic forms, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0105481A3 (en) | Pharmaceutical compositions containing clarithromycin and process for their preparation and their use | |
| HUP0203032A3 (en) | Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their use | |
| HUP0201315A3 (en) | 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0204394A3 (en) | Tetrahydropyridines, process for their preparation, pharmaceutical compositions containing them and use thereof | |
| HUP0201457A3 (en) | Eplerenone crystalline form, pharmaceutical compositions containing them and their preparations | |
| HUP0201797A3 (en) | 3-amino-2-benzyl-1-phenyl-propane derivatives, process for their preparation, pharmaceutical compositions containing them and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |